---
document_datetime: 2025-12-19 12:33:20
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/replagal-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: replagal-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.270678
conversion_datetime: 2025-12-27 14:02:19.418088
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Replagal

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | B.II.f.1.b Extension of the shelf life of the | 17/12/2025                          |                                             | SmPC                             |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000310907   | finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |     |                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------|
| Variation type IA / | This was an application for a group of variations. A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted | 09/12/2025 | N/A | EMA/VR/0000315349 |

<div style=\"page-break-after: always\"></div>

|                                       | in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted                                                                                                                                                                                                                                                             |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000288459 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Change(s) in the SmPC, labelling or package leaflet of human medicinal products in order to adapt to a recommendation of a competent authority , e.g. a Core SmPC, following the assessment of an Urgent Safety Restriction etc. Implementation of wording agreed by the competent authority that require additional minor assessment, e.g. translations are not yet agreed upon. - Accepted C.I.z (Type IB) - To update the excipients information in Section 6.1 of the SmPC, Section 3 of the Labeling, and Section 2 and 6 of the PL based on the Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use'. | 17/09/2025 | SmPC, Annex II, Labelling and PL | To update the excipients information in Section 6.1 of the SmPC, Section 3 of the Labeling, and Section 2 and 6 of the PL based on the Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use'. Furthermore, the MAH included Braille in accordance with Article 56a of Directive 2001/83/EC following the CHMP opinion dated 21 Jul 2022 for the procedure EMEA/H/C/000369/II/0117, where self- administration by a trained patient and/or a caregiver is added as a new method of administration. The impacted sections are updated accordingly. |

<div style=\"page-break-after: always\"></div>

| accordance with Article 56a of Directive 2001/83/EC following the CHMP opinion dated 21 Jul 2022 for the procedure EMEA/H/C/000369/II/0117, where self- administration by a trained patient and/or a caregiver is added as a new method of administration. The impacted sections are updated accordingly.  In addition, the MAH took the opportunity to implement editorial updates, including: • Updating Replagal carton and vial label mock-ups to improve readability and compliance, in accordance with the Guideline on the Readability of the Labelling and Package Leaflet of Medicinal Products for Human Use • Updating the PI throughout to align with the QRD template • Correcting typographical errors • Updating the ADR table in Section 4.8 of the SmPC to align terminology with MedDRA version 27.0 • Updating the list of the local representatives and removing the local representative for UK (NI), in alignment with the QRD template • Updating the PI in CZ, LT, SK, FR, IT, HR, PL, and SI to correct typographical errors; move the AE term 'dizziness' to the correct frequency; add the missing AE term 'throat tightness'; delete the alternative/duplicate AE term for 'abdominal discomfort'; correct translation mistakes; align volume units with the Compilation of QRD Decisions on Stylistic Matters in Product Information; and ensure   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                       | overall alignment with the QRD template.                                                                                                                                                                                                                              |            |     |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA / EMA/VR/0000268110 | A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted | 21/05/2025 | N/A |